NEWS
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has announced the publication of a manuscript in PLOS ONEdetailing the effectiveness of their pre-clinical HDAC inhibitor asset, SP-1-303. The study shows that SP-1-303 activates ATM protein and modulates estrogen receptor expression, resulting in significant growth inhibition of estrogen receptor positive breast cancer cells (ER + BC).
SP-1-303, developed in Shuttle Pharma's laboratories, is a selective Class I HDAC inhibitor that targets HDAC1, 3, and 6. It demonstrates direct cellular toxicity in ER + BC and increases PD-L1 expression, suggesting potential for combination therapy with immune checkpoint blockers. The research, conducted by Dr. Mira Jung and Dr. Scott Grindrod, highlights SP-1-303's promising therapeutic approach for treating ER + breast cancers.
SP-1-303, developed in Shuttle Pharma's laboratories, is a selective Class I HDAC inhibitor that targets HDAC1, 3, and 6. It demonstrates direct cellular toxicity in ER + BC and increases PD-L1 expression, suggesting potential for combination therapy with immune checkpoint blockers. The research, conducted by Dr. Mira Jung and Dr. Scott Grindrod, highlights SP-1-303's promising therapeutic approach for treating ER + breast cancers.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment